Information Provided By:
Fly News Breaks for November 20, 2015
RARE
Nov 20, 2015 | 07:28 EDT
Jefferies analyst Gena Wang says her due diligence ahead of KRN23 Phase 2 40-week bone data in pedi-XLH suggests drug effect might be modest, though likely clinically meaningful. Any stock weakness would present a buying opportunity as full drug effect should be seen with longer follow up, Wang tells investors in a research note. She keeps a Buy rating on Ultragenyx with a $118 price target. The data is expected by year-end.
News For RARE From the Last 2 Days
There are no results for your query RARE